Incretin Atlas › Trials › Amycretin s.c. phase 1b/2a
Amycretin s.c. phase 1b/2a
Amycretin · obesity
Design
- Molecule(s)
- Amycretin
- Population
- obesity
- Phase
- 1b/2a
- Participants
- 125
- Duration
- 36 weeks
Results by arm
| Arm | Population | Weeks | n | Weight, efficacy | Weight, treatment-policy | HbA1c, pp | AE discontinuation, % | Any discontinuation, % | Nausea, % | Vomiting, % | SAE, % | SBP, mmHg | Status |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| amycretin 60 mg | obesity | 36 | 125 | −24.3 % vs −1.1 % Δ −23.2 pp | — | −0.6 vs −0.1 | — | — | 82.0 vs 60.0 | 47.0 vs 60.0 | 0.0 vs 0.0 | — | verified |
| amycretin 20 mg | obesity | 36 | 125 | −22.0 % vs +2.0 % Δ −24.0 pp | — | −0.3 vs −0.1 | — | — | 79.0 vs 40.0 | 53.0 vs 20.0 | 3.0 vs 0.0 | — | verified |
Weight: percent change from baseline, drug vs placebo or comparator, Δ = difference in percentage points. Efficacy estimand = effect while on treatment (hypothetical strategy); treatment-policy = all randomised participants regardless of adherence (ITT). AE discontinuation = stopped study drug for any adverse event. Hover a status for its definition.
Notes
- amycretin 20 mg: The paper reports «events leading to withdrawal» (21 % vs 20 % placebo, part C), not discontinuation of the study drug.
Verbatim quotes from the source (9)
- amycretin 60 mg · nausea · Table 2 (Parts B–E; columns: 60 mg [B], pbo B, 20 mg [C], pb
Nausea 14 (82%), 17 3 (60%), 3 27 (79%), 36 2 (40%), 2 12 (75%), 12 1 (25%), 1 8 (50%), 8 2 (50%), 2
- amycretin 60 mg · vomiting · Table 2 (Parts B–E; columns: 60 mg [B], pbo B, 20 mg [C], pb
Vomiting 8 (47%), 15 3 (60%), 3 18 (53%), 20 1 (20%), 1 4 (25%), 5 0 5 (31%), 5 1 (25%), 1
- amycretin 60 mg · sae · Table 2 (Parts B–E; columns: 60 mg [B], pbo B, 20 mg [C], pb
Yes 0 0 1 (3%), 1 0 0 0 0 0
- amycretin 60 mg · hba1c · Table 3, Glycated haemoglobin rows
Estimated change from baseline to EOT –0·6% (0·1) –0·1% (0·2)
- amycretin 20 mg · weight_eff · Table 3
Estimated change from baseline to EOT –24·3% (1·9) –1·1% (3·0) –22·0% (1·0) 1·9% (2·5) –16·2% (1·1) 2·3% (1·8) –9·7% (1·3) 2·0% (2·4)
- amycretin 20 mg · nausea · Table 2 (Parts B–E; columns: 60 mg [B], pbo B, 20 mg [C], pb
Nausea 14 (82%), 17 3 (60%), 3 27 (79%), 36 2 (40%), 2 12 (75%), 12 1 (25%), 1 8 (50%), 8 2 (50%), 2
- amycretin 20 mg · vomiting · Table 2 (Parts B–E; columns: 60 mg [B], pbo B, 20 mg [C], pb
Vomiting 8 (47%), 15 3 (60%), 3 18 (53%), 20 1 (20%), 1 4 (25%), 5 0 5 (31%), 5 1 (25%), 1
- amycretin 20 mg · sae · Table 2
Yes 0 0 1 (3%), 1 0 0 0 0 0
- amycretin 20 mg · hba1c · Table 3
Estimated change from baseline to EOT –0·6% (0·1) –0·1% (0·2) –0·3% (0·1) –0·1% (0·1) –0·2% (0·1) 0·1% (0·1) –0·2% (0·1) –0·1% (0·1)
Primary sources
How to cite this page
Medical Adviser's Group. Incretin Atlas: Amycretin s.c. phase 1b/2a. Data cut 12 November 2026. https://docs.mdwrt.app/infographics/incretin-atlas/trials/amycretin-s-c-phase-1b-2a/ Data: doi:10.5281/zenodo.23473913. Accessed 16 November 2026.
Cite the primary publication for any single result; every value above links to it.